Literature DB >> 21222484

Effect of the thymidylate synthase inhibitors on dUTP and TTP pool levels and the activities of DNA repair glycosylases on uracil and 5-fluorouracil in DNA.

Breeana C Grogan1, Jared B Parker, Amy F Guminski, James T Stivers.   

Abstract

n class="Chemical">5-Fluorouracil (n class="Chemical">5-FU), 5-fluorodeoxyuridine (5-dUrd), and raltitrixed (RTX) are anticancer agents that target thymidylate synthase (TS), thereby blocking the conversion of dUMP into dTMP. In budding yeast, 5-FU promotes a large increase in the dUMP/dTMP ratio leading to massive polymerase-catalyzed incorporation of uracil (U) into genomic DNA, and to a lesser extent 5-FU, which are both excised by yeast uracil DNA glycosylase (UNG), leading to DNA fragmentation and cell death. In contrast, the toxicity of 5-FU and RTX in human and mouse cell lines does not involve UNG, but, instead, other DNA glycosylases that can excise uracil derivatives. To elucidate the basis for these divergent findings in yeast and human cells, we have investigated how these drugs perturb cellular dUTP and TTP pool levels and the relative abilities of three human DNA glycosylases (hUNG2, hSMUG1, and hTDG) to excise various TS drug-induced lesions in DNA. We found that 5-dUrd only modestly increases the dUTP and dTTP pool levels in asynchronous MEF, HeLa, and HT-29 human cell lines when growth occurs in standard culture media. In contrast, treatment of chicken DT40 B cells with 5-dUrd or RTX resulted in large increases in the dUTP/TTP ratio. Surprisingly, even though UNG is the only DNA glycosylase in DT40 cells that can act on U·A base pairs derived from dUTP incorporation, an isogenic ung(-/-) DT40 cell line showed little change in its sensitivity to RTX as compared to control cells. In vitro kinetic analyses of the purified human enzymes show that hUNG2 is the most powerful catalyst for excision of 5-FU and U regardless of whether it is found in base pairs with A or G or present in single-stranded DNA. Fully consistent with the in vitro activity assays, nuclear extracts isolated from human and chicken cell cultures show that hUNG2 is the overwhelming activity for removal of both U and 5-FU, despite its bystander status with respect to drug toxicity in these cell lines. The diverse outcomes of TS inhibition with respect to nucleotide pool levels, the nature of the resulting DNA lesion, and the DNA repair response are discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21222484      PMCID: PMC3074591          DOI: 10.1021/bi102046h

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  36 in total

1.  Separating substrate recognition from base hydrolysis in human thymine DNA glycosylase by mutational analysis.

Authors:  U Hardeland; M Bentele; J Jiricny; P Schär
Journal:  J Biol Chem       Date:  2000-10-27       Impact factor: 5.157

2.  Biphasic kinetics of the human DNA repair protein MED1 (MBD4), a mismatch-specific DNA N-glycosylase.

Authors:  F Petronzelli; A Riccio; G D Markham; S H Seeholzer; J Stoerker; M Genuardi; A T Yeung; Y Matsumoto; A Bellacosa
Journal:  J Biol Chem       Date:  2000-10-20       Impact factor: 5.157

3.  hUNG2 is the major repair enzyme for removal of uracil from U:A matches, U:G mismatches, and U in single-stranded DNA, with hSMUG1 as a broad specificity backup.

Authors:  Bodil Kavli; Ottar Sundheim; Mansour Akbari; Marit Otterlei; Hilde Nilsen; Frank Skorpen; Per Arne Aas; Lars Hagen; Hans E Krokan; Geir Slupphaug
Journal:  J Biol Chem       Date:  2002-08-02       Impact factor: 5.157

4.  Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.

Authors:  M Meyers; M W Wagner; H S Hwang; T J Kinsella; D A Boothman
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

Review 5.  Uracil in DNA--occurrence, consequences and repair.

Authors:  Hans E Krokan; Finn Drabløs; Geir Slupphaug
Journal:  Oncogene       Date:  2002-12-16       Impact factor: 9.867

Review 6.  Role of MED1 (MBD4) Gene in DNA repair and human cancer.

Authors:  A Bellacosa
Journal:  J Cell Physiol       Date:  2001-05       Impact factor: 6.384

7.  Excision of deaminated cytosine from the vertebrate genome: role of the SMUG1 uracil-DNA glycosylase.

Authors:  H Nilsen; K A Haushalter; P Robins; D E Barnes; G L Verdine; T Lindahl
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

Review 8.  Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.

Authors:  B Van Triest; H M Pinedo; G Giaccone; G J Peters
Journal:  Ann Oncol       Date:  2000-04       Impact factor: 32.976

Review 9.  DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets.

Authors:  Long Shan Li; Julio C Morales; Martina Veigl; David Sedwick; Sheldon Greer; Mark Meyers; Mark Wagner; Richard Fishel; David A Boothman
Journal:  Br J Pharmacol       Date:  2009-09-23       Impact factor: 8.739

Review 10.  5-fluorouracil: mechanisms of action and clinical strategies.

Authors:  Daniel B Longley; D Paul Harkin; Patrick G Johnston
Journal:  Nat Rev Cancer       Date:  2003-05       Impact factor: 60.716

View more
  35 in total

1.  DNA synthesis as a therapeutic target: the first 65 years.

Authors:  Christopher K Mathews
Journal:  FASEB J       Date:  2012-06       Impact factor: 5.191

Review 2.  TAS-102, a novel antitumor agent: a review of the mechanism of action.

Authors:  Heinz-Josef Lenz; Sebastian Stintzing; Fotios Loupakis
Journal:  Cancer Treat Rev       Date:  2015-06-06       Impact factor: 12.111

Review 3.  The curious chemical biology of cytosine: deamination, methylation, and oxidation as modulators of genomic potential.

Authors:  Christopher S Nabel; Sara A Manning; Rahul M Kohli
Journal:  ACS Chem Biol       Date:  2011-10-31       Impact factor: 5.100

Review 4.  The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence.

Authors:  William H Gmeiner; Waldemar Debinski; Carol Milligan; David Caudell; Timothy S Pardee
Journal:  Future Oncol       Date:  2016-06-09       Impact factor: 3.404

5.  Diverse fates of uracilated HIV-1 DNA during infection of myeloid lineage cells.

Authors:  Erik C Hansen; Monica Ransom; Jay R Hesselberth; Nina N Hosmane; Adam A Capoferri; Katherine M Bruner; Ross A Pollack; Hao Zhang; Michael Bradley Drummond; Janet M Siliciano; Robert Siliciano; James T Stivers
Journal:  Elife       Date:  2016-09-20       Impact factor: 8.140

6.  Glycogen Synthase Kinase 3 (GSK-3)-mediated Phosphorylation of Uracil N-Glycosylase 2 (UNG2) Facilitates the Repair of Floxuridine-induced DNA Lesions and Promotes Cell Survival.

Authors:  Carly A Baehr; Catherine J Huntoon; Song-My Hoang; Calvin R Jerde; Larry M Karnitz
Journal:  J Biol Chem       Date:  2016-11-14       Impact factor: 5.157

7.  Disordered N-Terminal Domain of Human Uracil DNA Glycosylase (hUNG2) Enhances DNA Translocation.

Authors:  Gaddiel Rodriguez; Alexandre Esadze; Brian P Weiser; Joseph D Schonhoft; Philip A Cole; James T Stivers
Journal:  ACS Chem Biol       Date:  2017-08-15       Impact factor: 5.100

8.  SMUG1 but not UNG DNA glycosylase contributes to the cellular response to recovery from 5-fluorouracil induced replication stress.

Authors:  Pratik Nagaria; David Svilar; Ashley R Brown; Xiao-Hong Wang; Robert W Sobol; Michael D Wyatt
Journal:  Mutat Res       Date:  2012-12-17       Impact factor: 2.433

9.  Triamcinolone acetonide combined with 5-fluorouracil suppresses urethral scar fibroblasts autophagy and fibrosis by increasing miR-192-5p expression.

Authors:  Weidong Zhou; Qingsong Yu; Junjie Ma; Chengdang Xu; Denglong Wu; Chao Li
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

10.  Uracil DNA glycosylase initiates degradation of HIV-1 cDNA containing misincorporated dUTP and prevents viral integration.

Authors:  Amy F Weil; Devlina Ghosh; Yan Zhou; Lauren Seiple; Moira A McMahon; Adam M Spivak; Robert F Siliciano; James T Stivers
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.